Allen C Eaves

Education^
Born in Ottawa, Eaves moved at an early age toCoulombel l et al. Long-term marrow culture reveals
Nova Scotia. Interested in science, he attendedchromosomally normal hematopoietic progenitor cells
Acadia University and graduated with a BSc in Biologyin patients with Philadelphia chromosome-positive
and Mathematics in 1962. He then went to Dalhousiechronic myelogenous leukemia. N Engl J Med
University, completing his MSc in cell physiology under308:1493-1498, 1983.
Dr. Gordon Kaplan on A Radiological Investigation ofEaves AC, et al. Unregulated proliferation of primitive
Two Cellular Enzyme Systems of Yeast (1964). Thechronic myeloid leukemic progenitors in the presence
untimely cancer death of a family friend led him toof normal marrow adherent cells. Proc Natl Acad Sci
switch to medicine, completing his MD and internshipUSA 83: 5306-5310, 1986.
in 1969. During his medical training he was greatlyBarnet MJ et al. Successful autografting in chronic
influenced by Dr. Ross Langley, a research-orientedmyelogenous leukemia after maintenance of marrow
hematologist who suggested that Eaves do a PhD atin culture. Bone Marrow Transplant 4: 345-351, 1989.
the Princess Margaret Hospital in Toronto where Dr.Eaves CJ & Eaves AC. Erythropoietin (EP)
Robert Bruce was collaborating with Drs. James Tilldose-response curves for three classes of erythroid
and Ernest McCulloch (Lasker Award) on howprogenitors in normal and in patients with
different types of cancer chemotherapeutic agentspolycythemia vera. Blood 52: 1196-1210, 1978.
killed tumour stem cells while sparing normal stemCashman JD, et al. Unregulated proliferation of
cells.primitive neoplastic progenitor cells in long-term
Working under the supervision of Bruce (AACRpolycythemia vera marrow cultures. J Clin Invest
Award), and in association with Till and McCulloch and81:87-91, 1988.
a vibrant group of graduate students andHogge DE, Coulombel L, Kalousek DK, Eaves CJ
post-doctoral fellows, Eaves completed his PhD in& Eaves AC. Nonclonal hemopoietic progenitors
Medical Biophysics at the University of Toronto within a G6PD heterozygote with chronic myelogenous
a thesis entitled Studies on the Control of Murineleukemia revealed after long-term marrow culture.
Bone Marrow Function (1974). Eaves then decided toAm J Hematol 24: 389-394, 1987.
complete his clinical specialist training in InternalHogge DE, Shannon KM, Kalousek DK, Schonberg S,
Medicine and Medical Oncology in Canada so that heSchaffner V, Zoger S, Eaves CJ & Eaves AC.
could be licensed to work in Canada and have accessJuvenile monosomy 7 syndrome: Evidence that the
to human material for studying leukemia directly indisease originates in a pluripotent hemopoietic stem
humans, rather than in mice. He received this furthercell. Leuk Res 11: 705-709, 1987.
clinical training in Toronto and Vancouver, becoming aTurhan AG, Humphries RK, Cashman JD, Cuthbert
Fellow of the Royal College of Physicians andDA, Eaves CJ & Eaves AC. Transient
Surgeons (FRCPC) in 1979 and a Fellow of thesuppression of clonal hemopoiesis associated with
American College of Physicians (FACP) in 1980. Hepregnancy in a patient with a myeloproliferative
then joined the staff of the British Columbia Cancerdisorder. J Clin Invest 81: 1999-2003, 1988.
Agency (BCCA), the Vancouver General Hospital andBarnett MJ, Eaves CJ, Phillips GL, Kalousek DK,
the University of British Columbia in 1979 as anKlingemann H-G, Lansdorp PM, Reece DE, Shepherd
assistant professor, becoming associate professor inJD, Shaw GJ & Eaves AC. Successful
1984, professor in 1989 and Professor Emeritus ofautografting in chronic myeloid leukaemia after
Hematology in 2006.maintenance of marrow in culture. Bone Marrow
CareerTransplant 4: 345-351, 1989.
In 1981, as one of the first Scholars of the BC HealthBarnett MJ, Eaves CJ, Phillips GL, Kalousek DK,
Care Research Foundation, Eaves founded the TerryKlingemann H-G, Lansdorp PM, Reece DE, Shepherd
Fox Laboratory for Hematology. As Director of theJD, Shaw GJ & Eaves AC. Successful
TFL over the next 25 years, he built the TFL into anautografting in chronic myeloid leukaemia after
internationally recognized research group with a staffmaintenance of marrow in culture. Bone Marrow
of over 150 including 13 senior scientists, 35 graduateTransplant 4: 345-351, 1989.
students and 40 post doctoral fellows ( The TFL is aSzilvassy SJ, Fraser CC, Eaves CJ, Lansdorp PM,
leader in understanding the regulation ofEaves AC & Humphries RK. Retrovirus-mediated
hematopoietic (blood-forming) stem cell growth andgene transfer to purified hemopoietic stem cells with
differentiation. The TFL played a leadership role inlong-term lympho-myelopoietic repopulating ability.
obtaining the CFI grant that initiated funding for theProc Natl Acad Sci USA 86: 8798-8802, 1989.
new $100 million, 15 storey, BC Cancer ResearchTurhan AG, Humphries RK, Phillips GL, Eaves AC
Centre (opened on March 1, 2005), where the TFL& Eaves CJ. Clonal hematopoiesis demonstrated
occupies the top several floors of this cutting-edgeby X-linked DNA polymorphisms after allogeneic bone
facility. Eaves personal research has focused onmarrow transplantation. N Engl J Med 320: 1655-1661,
leukemia where he pioneered ulture purging as a1989.
novel approach to doing autologous bone marrowSutherland HJ, Lansdorp PM, Henkelman DH, Eaves
transplantation for chronic myelogenous leukemia. HeAC & Eaves CJ. Functional characterization of
has over 200 papers in leading peer-review scientificindividual human hematopoietic stem cells cultured at
journals. In 2003 he was awarded the prestigious R.limiting dilution on supportive marrow stromal layers.
M. Taylor Medal by the Canadian Cancer Society andProc Natl Acad Sci USA 87: 3584-3588, 1990.
the National Cancer Institute of Canada.Szilvassy SJ, Humphries RK, Lansdorp PM, Eaves AC
In 1985 Eaves became Head of Hematology at UBC,& Eaves CJ. Quantitative assay for totipotent
the VGH and the BCCA where for the next 18 yearsreconstituting hematopoietic stem cells by a
he focused on building the world class Leukemia/Bonecompetitive repopulation strategy. Proc Natl Acad Sci
Marrow Transplant (BMT) Program of British Columbia.USA 87: 8736-8740, 1990.
This was one of the first BMT programs in CanadaTurhan AG, Humphries RK, Eaves CJ, Barnett MJ,
and by the early 1990 over 1500 patients had beenPhillips GL, Kalousek DK, Klingemann H-G, Lansdorp
transplanted of which 300 were from other provincesPM, Reece DE, Shepherd JD & Eaves AC.
(generating revenue for BC of over $30 million). TheDetection of breakpoint cluster region-negative and
program also trained a significant number of BMTnonclonal hematopoiesis in vitro and in vivo after
specialists, many of whom have played a role intransplantation of cells selected in cultures of chronic
starting BMT programs elsewhere in Canada andmyeloid leukemia marrow. Blood 76: 2404-2410, 1990.
abroad. In recognition of his interests in BMT he wasUdomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett
elected President of the International Society of CellMJ & Eaves AC. Rapid decline of chronic myeloid
Therapy(1995-97), President of the American Societyleukemic cells in long-term culture due to a defect at
of Blood and Marrow Transplantation (1999-00) andthe leukemic stem cell level. Proc Natl Acad Sci USA
Treasurer of the Foundation for the Accreditation of89: 6192-6196, 1992.
Cellular Therapy (1995-2002). He has also been aEaves CJ, Cashman JD, Wolpe SD & Eaves AC.
member of Health Canada Expert Working Group onUnresponsiveness of primitive chronic myeloid
the Safety of Organs and Tissues forleukemia cells to macrophage inflammatory protein 1a,
Transplantation, and the Canadian Standardsan inhibitor of primitive normal hematopoietic cells.
Association Task Force to develop standards and anProc Natl Acad Sci USA 90: 12015-12019, 1993.
accreditation process for cellular therapies andPetzer AL, Eaves CJ, Lansdorp PM, Ponchio L,
transplantation in Canada (1998-2006).Barnett MJ & Eaves AC. Characterization of
In the 1980, to raise money to support running theprimitive subpopulations of normal and leukemic cells
Terry Fox Laboratory, Eaves sold urinarypresent in the blood of patients with newly diagnosed
erythropoietin and tissue culture reagents to researchas well as established chronic myeloid leukemia. Blood
colleagues around the world. By the early 1990 it88: 2162-2171, 1996.
became necessary to make the tissue culture mediaCashman JD, Eaves CJ, Sarris AH & Eaves AC.
in a clean room. However, the BC Cancer FoundationMCP-1, not MIP-1a is the endogenous chemokine that
did not have the $1 million needed to build such acooperates with TGF-b to inhibit the cycling of
facility and encouraged Eaves to buy the businessprimitive normal but not leukemic (CML) progenitors in
from them and raise the money himself, which he didlong-term human marrow cultures. Blood 92:
by fully mortgaging his home and obtaining a loan2338-2344, 1998.
from Western Economic Diversification. Starting withJiang X, Lopez A, Holyoake T, Eaves A & Eaves
8 employees in 1993, STEMCELL Technologies IncC. Autocrine production and action of IL-3 and
has grown at 20 to 30% per annum and in Januarygranulocyte colony-stimulating factor in chronic
2010 had over 320 employees. STEMCELL is themyeloid leukemia. Proc Natl Acad Sci USA 96:
largest biotech company in BC in terms of BC-based12804-12809, 1999.
employees. It has 800 products in its catalogue, theJiang X, Fujisaki T, Nicolini F, Berger M, Holyoake T,
lead ones all made in its manufacturing facility inEisterer W, Eaves C & Eaves A. Autonomous
Vancouver. STEMCELL remains profitable with 2010multi-lineage differentiation in vitro of primitive CD34+
sales of $50 million. An internationally competitive andcells from patients with chronic myeloid leukemia.
export-orientated company, 95% of its customersLeukemia 14: 1112-1121, 2000.
are outside of Canada. In addition to its VancouverHolyoake TL, Jiang X, Jorgensen HG, Graham S,
facilities, STEMCELL has distribution and sales officesAlcorn MJ, Laird C, Eaves AC & Eaves CJ.
in the USA, Europe, Australia and Singapore plusPrimitive quiescent leukemic cells from patients with
distributors in all other major countries. A spin-offchronic myeloid leukemia spontaneously initiate
company, STEMSOFT Software Inc, makes softwarefactor-independent growth in vitro in association with
for managing data in BMT centres, cord blood banks,up-regulation of expression of interleukin-3. Blood 97:
cellular therapy companies and tumour/tissue720-728, 2001.
repositories. A second spin-off, MalachiteCashman J, Dykstra B, Clark-Lewis I, Eaves A &
Management Inc, does society and meetingEaves C. Changes in the proliferative activity of
management for such organizations as the Canadianhuman hematopoietic stem cells in NOD/SCID mice
Blood and Marrow Transplant Group, the Internationaland enhancement of their transplantability after in
Society for Cell Therapy, the American Society forvivo treatment with cell cycle inhibitors. J Exp Med
Aphaeresis and the Canadian Association of Oncology196: 1141-1149, 2002.
Nurses. As of 2010, the STEMCELL Group had 260Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E,
employees in Vancouver, most of whom are locatedKennedy S, Nicolini F, Eaves A & Eaves C.
in the STEMCELL Building at 570 West SeventhDeregulated expression in Ph+ human leukemias of
Avenue. It should be noted that STEMCELLAHI-1, a gene activated by insertional mutagenesis in
Technologies Inc supports Canada Networks ofmouse models of leukemia. Blood 103: 3897-3904,
Centres of Excellence (NCE) Program, including: the2004.
Stem Cell Network where STEMCELL TechnologiesINTERNAL WIKIPEDIA LINKS
Inc is the major corporate supporter and Eaves is aJames Till
member of the Board, and the Mathematics ofErnest McCulloch
Information Technology and Complex SystemsConnie Eaves
where Eaves is Chairman of the Board of Directors.Stem Cells
Eaves is passionate about helping British ColumbiaHematopoiesis
become a more science-oriented culture andHematopoietic stem cells
economy that is knowledge-based, high tech andCellular therapy
environmentally friendly.Bone marrow transplantation
HonoursChronic myelogenous leukemia
National Cancer Institute of Canada Fellowship,Polycythemia vera
1979-1974Terry Fox Laboratory
Research Scholar, British Columbia Health CareBC Cancer Research Centre
Research Foundation, 19791983BC Cancer Agency
Distinguished Alumni Service award, Acadia University,External links
1997Leukemia/Bone Marrow Transplant Program of British
Polish National Hematology Society Medal, 2000Columbia
Distinguished Medical Lecture Award, University ofCanadian Cancer Society
British Columbia, 2001STEMCELL Technologies Inc
R.M. Taylor Medal, Canadian Cancer Society andSTEMSOFT Software Inc
Nationals Cancer Institute of Canada, 2002Malachite Management Inc
Lifetime Membership Award, International Society ofMathematics of Information Technology and Complex
Cell Therapy, 2002Systems
Genome BC Award for Scientific ExcellenceCanadian Stem Cell Network
(Co-recipient with Dr. Connie Eaves), 2007Robert Bruce Am. Assoc.
References